MedTrace Logo

Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

NCT04868292 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2021-11-17

No results posted yet for this study

Summary

To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

SPR206

Three 100 mg SPR206 intravenous doses administered every 8 hours

Sponsors & Collaborators

  • United States Department of Defense

    collaborator FED

  • Spero Therapeutics

    lead INDUSTRY

Principal Investigators

  • David Melnick, MD · Spero Therapeutics Inc

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-06-03
Primary Completion
2021-09-16
Completion
2021-09-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04868292 on ClinicalTrials.gov